Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1979 1
1982 2
1983 1
1984 1
1985 1
1986 2
1987 1
1989 1
1991 1
1992 1
1994 1
1995 2
1996 6
1997 7
1998 7
1999 5
2000 6
2001 6
2002 8
2003 11
2004 4
2005 7
2006 5
2007 6
2008 10
2009 10
2010 8
2011 13
2012 15
2013 16
2014 13
2015 16
2016 14
2017 9
2018 8
2019 11
2020 8
2021 12
2022 6
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

258 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. González-Martín A, et al. Among authors: freyer g. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562799 Clinical Trial.
Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
González-Martín A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, Freyer G, Backes F, Heitz F, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Malinowska IA, Shtessel L, Compton N, Mirza MR, Monk BJ. González-Martín A, et al. Among authors: freyer g. Eur J Cancer. 2023 Aug;189:112908. doi: 10.1016/j.ejca.2023.04.024. Epub 2023 May 3. Eur J Cancer. 2023. PMID: 37263896 Free article. Clinical Trial.
Véronique Trillet-Lenoir.
Freyer G. Freyer G. Bull Cancer. 2023 Oct 16:S0007-4551(23)00382-X. doi: 10.1016/j.bulcan.2023.09.003. Online ahead of print. Bull Cancer. 2023. PMID: 37852800 French. No abstract available.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. de Gramont A, et al. Among authors: freyer g. J Clin Oncol. 2000 Aug;18(16):2938-47. doi: 10.1200/JCO.2000.18.16.2938. J Clin Oncol. 2000. PMID: 10944126 Corrected and republished. Clinical Trial.
Traitement des rechutes tardives du cancer de l’ovaire.
Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard AC, You B. Floquet A, et al. Among authors: freyer g. Bull Cancer. 2017 May;104 Suppl 1:S24-S31. doi: 10.1016/S0007-4551(17)30159-5. Bull Cancer. 2017. PMID: 28625312 French.
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. You B, et al. Among authors: freyer g. Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24. Clin Cancer Res. 2020. PMID: 32209570 Clinical Trial.
[CHIP and ovarian cancer].
Lécuru F, Bakrin N, Classe JM, Colombo PE, Ferron G, Freyer G, Glehen O, Gouy S, Huchon C, Narducci F, Pocard M, Pomel C, Rouzier R. Lécuru F, et al. Among authors: freyer g. Gynecol Obstet Fertil Senol. 2019 Sep;47(9):617-618. doi: 10.1016/j.gofs.2019.06.007. Epub 2019 Jun 26. Gynecol Obstet Fertil Senol. 2019. PMID: 31252153 French. No abstract available.
First-line therapy in ovarian cancer trials.
Thigpen T, duBois A, McAlpine J, DiSaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup. Thigpen T, et al. Among authors: freyer g. Int J Gynecol Cancer. 2011 May;21(4):756-62. doi: 10.1097/IGC.0b013e31821ce75d. Int J Gynecol Cancer. 2011. PMID: 21543937 Review.
258 results